Date: Monday, October 22, 2018
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Lupus Impact Tracker (LIT) is a ten item unidimensional patient reported outcome tool developed from and for patients with systemic lupus erythematosus (SLE). It has been widely validated and shown to have good psychometric properties and responsiveness, to patient reported changes in health, physician based disease activity and composite response Index. Herein we report functioning of LIT in the largest European SLE registry cohort.
Methods: Multi-center data collected prospectively, two years apart, from 1,364 adult patients SLE meeting 1997 ACR criteria were obtained. This included demographics, patient reported tools (LIT, EuroQoL- EQ5D) and SLE (activity-SLEDAI & SLAQ; damage-SDI). We evaluated LIT for reliability (Internal consistency), validity (construct (convergent and factor analysis), and criterion). Cronbach alpha was obtained for internal consistency reliability. Spearman correlation coefficient (r) of LIT against EQ5D and factor analysis were obtained for Construct validity. Correlation of LIT with SLEDAI, SLAQ and SDI were made for Criterion Validity. Responsiveness of LIT to changes in SLEDAI (cutoff 5) and SLAQ (cutoff 5) from baseline and year 1 data were obtained using mixed model analysis.
Results: 1232/1364 (90%) were women, and 95% were Caucasian. Mean (SD) SLEDAI, NRS-SLAQ and SDI were 2.6 (3.5), 3.1 (2.5) and 0.7 (1.1) respectively. Mean (SD) LIT and EQ5D VAS were 29.2 (23.2) and 67.3 (21.4). Internal consistency reliability of LIT was good (Cronbach α 0.92). Construct-convergent validity with EQ5D domains and VAS were as follows: Mobility (r 0.46, p<0.001), Self-Care (r 0.38, p<0.001), Usual Activities (r 0.62, p <0.001), Pain/Discomfort (r 0.63, p<0.001), Anxiety/Depression (r 0.60, p<0.001), and EQ5D-VAS (r-0.62, p<0.001). Single factor explained 58% of variance in LIT (Eigenvalue 5.8), confirming its uni-dimensionality and construct validity. LIT scores were correlated with SLEDAI (r 0.12, p<0.001), NRS-SLAQ (0.71, p<0.001 & 0.67, p<0.001) and SDI (0.16, p <0.001) supporting criterion validity. EQ5D VAS also correlated with SLEDAI, SLAQ and SDI. Mean decline in LIT in response to improvement in SLEDAI and SLAQ were -2.9 (SRM -0.17, ES 0.08, P 0.04) and -13.1 (SRM -0.74. ES -0.30, p <0.001); while mean increase in LIT in response to worsening in SLEDAI and SLAQ were 0.91 (SRM 0.04, ES 0.03, p 0.06) and 12.6 (SRM 0.65, ES 0.43, p <0.001) respectively.
Conclusion: Lupus Impact Tracker documented good measurement properties among Spanish SLE patients enrolled in this observational largest European SLE registry.
To cite this abstract in AMA style:Jolly M, Azizoddin DR, Rúa-Figueroa I, Devilliers H, Menor Almagro R, López Longo FJ, Ovalles-Bonilla JG, Olivé-Marqués A, Rubio-Muñoz P, Galindo M, Fernandez-Nebro A, Calvo-Alen J, García-Vicuña R, Tomero E, Uriarte Isacelaya E, Pecondon-Español A, Blanco R, Freire M, Gantes M, Ibanez Barcelo M, Montilla-Morales CA, Rosas J, García-Villanueva J, Vela P, Ruiz Lucea E, Toyos F, Hernández Beiraín J, Diez Alvarez E, Bonilla Hernán MG, Narváez FJ, Andréu-Sánchez J, Moreno-Martínez-Losa M, Sánchez Atrio A, Horcada ML, Cobo-Ibáñez T, Marras Fernandez-Cid C, Vazquez Rodriguez TR, Salgado-Pérez E, Torrente V, Alegre-Sancho J, Mouriño-Rodriguez C, Block JA, Pego-Reigosa J. Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/lupus-impact-tracker-validation-in-a-large-european-spanish-lupus-registry-cohort/. Accessed April 13, 2021.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-impact-tracker-validation-in-a-large-european-spanish-lupus-registry-cohort/